Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.64 |
| ▸ | RAB9A | P51151 | 9/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.64 |
| ▸ | RELA | Q04206 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.57 |
| ▸ | WNT3A | P56704 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638111 | 0.85 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL11716643 | 0.85 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL11716649 | 0.85 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL5291319 | 0.84 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL2638108 | 0.83 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL10605304 | 0.83 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL4413382 | 0.83 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL14580724 | 0.82 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL9870685 | 0.82 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL4856355 | 0.81 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110627718-A | Synthesis method of (E) -beta-monofluoroalkyl-beta, gamma-unsaturated amide | 安阳师范学院 | 2019-12-31 | — | — | CN | claimed |
| CN-110627718-B | Synthesis method of (E) -beta-monofluoroalkyl-beta, gamma-unsaturated amide | 安阳师范学院 | 2022-10-04 | — | — | CN | disclosed |
| CN-110627718-B | Synthesis method of (E) -beta-monofluoroalkyl-beta, gamma-unsaturated amide | 安阳师范学院 | 2022-10-04 | — | — | CN | disclosed |
| CN-110627718-A | Synthesis method of (E) -beta-monofluoroalkyl-beta, gamma-unsaturated amide | 安阳师范学院 | 2019-12-31 | — | — | CN | disclosed |
| CN-110627718-A | Synthesis method of (E) -beta-monofluoroalkyl-beta, gamma-unsaturated amide | 安阳师范学院 | 2019-12-31 | — | — | CN | disclosed |
| CN-108358978-A | A kind of enhancement magnetic targeted cell fluorescence nano-probe and preparation method thereof | 四川农业大学 | 2018-08-03 | — | — | CN | disclosed |
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-6995143-B2 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-02-07 | — | — | US | disclosed |
| EP-1478653-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2004-11-24 | — | — | EP | disclosed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | disclosed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212011-A1 | Macrolides with antibacterial activity | MRPL21, RPS21, MRPS18A | NPC1 133/4885RAB9A 766/4885SMN1; SMN2 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.